WO2017177032A3 - Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6 - Google Patents

Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6 Download PDF

Info

Publication number
WO2017177032A3
WO2017177032A3 PCT/US2017/026395 US2017026395W WO2017177032A3 WO 2017177032 A3 WO2017177032 A3 WO 2017177032A3 US 2017026395 W US2017026395 W US 2017026395W WO 2017177032 A3 WO2017177032 A3 WO 2017177032A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
seq
depression
chain variable
variable region
Prior art date
Application number
PCT/US2017/026395
Other languages
English (en)
Other versions
WO2017177032A2 (fr
Inventor
Guang Chen
Yu Sun
Dai Wang
Gayle WITTENBERG
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Priority to EP17779843.6A priority Critical patent/EP3440108A4/fr
Priority to AU2017248280A priority patent/AU2017248280A1/en
Priority to JP2018552798A priority patent/JP2019519470A/ja
Priority to CA3019828A priority patent/CA3019828A1/fr
Publication of WO2017177032A2 publication Critical patent/WO2017177032A2/fr
Publication of WO2017177032A3 publication Critical patent/WO2017177032A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode de traitement de la dépression ou de la fatigue chez un sujet consistant à administrer un agent qui bloque la liaison de l'IL-6 au récepteur de l'IL-6, par exemple, un anticorps anti-IL-6 ou un fragment de liaison à l'antigène de celui-ci qui peut comprendre une région variable de chaîne lourde et une région variable de chaîne légère de SEQ ID n° 99 et SEQ ID n° 97, respectivement, ou une région variable de chaîne lourde et une région variable de chaîne légère de SEQ ID n° 139 et SEQ ID n° 140, respectivement. L'invention concerne en outre un procédé permettant de déterminer la sensibilité d'un individu ayant une dépression à un traitement par anticorps anti-IL-6 ou un fragment de liaison à l'antigène de celui-ci, ledit procédé consistant à : (a) mesurer la quantité de récepteur soluble de l'IL-6 (sIL-6 R) dans un échantillon biologique provenant du sujet; (b) fournir une valeur seuil corrélant la quantité de sIL-6 R et la sensibilité; (c) comparer la quantité de sIL-6 R à la valeur seuil pour déterminer la sensibilité; et (d) traiter l'individu avec un agent qui bloque la liaison de l'IL-6 au récepteur de l'IL-6.
PCT/US2017/026395 2016-04-07 2017-04-06 Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6 WO2017177032A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP17779843.6A EP3440108A4 (fr) 2016-04-07 2017-04-06 Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6
AU2017248280A AU2017248280A1 (en) 2016-04-07 2017-04-06 Treatment of depression using agents that block binding of IL-6 to IL-6 receptor
JP2018552798A JP2019519470A (ja) 2016-04-07 2017-04-06 Ｉｌ−６受容体へのｉｌ−６の結合を遮断する薬剤を用いたうつ病の治療
CA3019828A CA3019828A1 (fr) 2016-04-07 2017-04-06 Traitement de la depression a l'aide d'agents qui bloquent la liaison de l'il-6 au recepteur de l'il-6

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319558P 2016-04-07 2016-04-07
US62/319,558 2016-04-07

Publications (2)

Publication Number Publication Date
WO2017177032A2 WO2017177032A2 (fr) 2017-10-12
WO2017177032A3 true WO2017177032A3 (fr) 2017-11-16

Family

ID=59998986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/026395 WO2017177032A2 (fr) 2016-04-07 2017-04-06 Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6

Country Status (7)

Country Link
US (1) US20170291942A1 (fr)
EP (1) EP3440108A4 (fr)
JP (1) JP2019519470A (fr)
AU (1) AU2017248280A1 (fr)
CA (1) CA3019828A1 (fr)
MA (1) MA44631A (fr)
WO (1) WO2017177032A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190345245A1 (en) * 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188502A1 (en) * 2001-11-14 2006-08-24 Jill Giles-Komar Anti-IL-6 antibodies, compositions, methods and uses
US20140099311A1 (en) * 2005-04-29 2014-04-10 Applied Molecular Evolution, Inc. Anti-IL-6 Antibodies, Compositions, Methods and Uses
US20140302058A1 (en) * 2009-01-29 2014-10-09 Medimmune, Llc Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
JP2015123031A (ja) * 2013-12-27 2015-07-06 国立大学法人 千葉大学 関節リウマチ患者に対する抗ｉｌ−６受容体抗体治療の有効性予測方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188502A1 (en) * 2001-11-14 2006-08-24 Jill Giles-Komar Anti-IL-6 antibodies, compositions, methods and uses
US20140099311A1 (en) * 2005-04-29 2014-04-10 Applied Molecular Evolution, Inc. Anti-IL-6 Antibodies, Compositions, Methods and Uses
US20140302058A1 (en) * 2009-01-29 2014-10-09 Medimmune, Llc Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
JP2015123031A (ja) * 2013-12-27 2015-07-06 国立大学法人 千葉大学 関節リウマチ患者に対する抗ｉｌ−６受容体抗体治療の有効性予測方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NAKANISHI ET AL.: "lnterleukin-6/Soluble Interleukin-6 Receptor Signaling Attenuates Proliferation And Invasion, And Induces Morphological Changes Of A Newly Established Pleomorphic Malignant Fibrous Histiocytoma Cell Line", AMERICAN JOURNAL OF PATHOLOGY., vol. 165, no. 2, 1 August 2004 (2004-08-01), pages 471 - 480, XP055579264, ISSN: 0002-9440, DOI: 10.1016/S0002-9440(10)63312-3 *
RHEE ET AL.: "A Phase 2, Open-label, Multicenter Study Of The Long-Term Safety Of Siltuximab (An Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman Disease", ONCOTARGET., vol. 6, no. 30, 3 August 2015 (2015-08-03), pages 30408 - 30419, XP055441655 *
See also references of EP3440108A4 *

Also Published As

Publication number Publication date
WO2017177032A2 (fr) 2017-10-12
EP3440108A2 (fr) 2019-02-13
EP3440108A4 (fr) 2020-01-08
US20170291942A1 (en) 2017-10-12
CA3019828A1 (fr) 2017-10-12
AU2017248280A1 (en) 2018-10-25
JP2019519470A (ja) 2019-07-11
MA44631A (fr) 2019-02-13

Similar Documents

Publication Publication Date Title
JOP20200213A1 (ar) جزيئات رابطة لـ pd-1 وطرق استخدامها
PH12020500643A1 (en) Anti-ngf antibodies and methods thereof
EP4303235A3 (fr) Molecules de liaison lag-3 et leurs procedes d'utilisation
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
EP3991748A3 (fr) Anticorps anti-sortiline et leurs procédés d'utilisation
JOP20190292A1 (ar) استخدام الأجسام المضادة لربط il-1? في علاج السرطان
MX2018012651A (es) Composiciones que comprenden coformulacion de anticuerpos anti-ligando-1 de muerte celular programada (pd-l1) y anti-antigeno-4 asociado a linfocitos t citotoxicos (ctla-4).
WO2018148486A8 (fr) Anticorps anti-facteur d et utilisations de ces derniers
ZA200806610B (en) Anti-IL-6 antibodies preventing the binding of IL-6 complexed with IL-6ralpha to GP130
MX2020010387A (es) Metodos para detectar y cuantificar fgf21.
MX2016005765A (es) Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos.
MX2022014422A (es) Anticuerpos contra el sars-cov-2 y metodos de seleccion y uso de los mismos.
PH12021551500A1 (en) Anti-ctla4 antibodies and methods of use thereof
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м
WO2019060750A3 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
BR112018072066A2 (pt) moléculas de ligação específicas para fcgamariia e uso das mesmas
WO2020006374A3 (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
WO2020128446A3 (fr) Anticorps btla
PH12020551373A1 (en) Anti-phf-tau antibodies and uses thereof
EP4300101A3 (fr) Peptides antigéniques et leurs utilisations pour diagnostiquer et traiter l'autisme
NZ750451A (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
EP4276108A3 (fr) Méthodes de traitement de maladies dans lesquelles l'activité de l'il-13 est préjudiciable à l'aide d'anticorps anti-il-13
WO2017177032A3 (fr) Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6
WO2018102594A8 (fr) Procédés de traitement de tumeurs solides avec des anticorps anti-cd200
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3019828

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018552798

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017248280

Country of ref document: AU

Date of ref document: 20170406

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017779843

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017779843

Country of ref document: EP

Effective date: 20181107

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17779843

Country of ref document: EP

Kind code of ref document: A2